Chinese Guidelines on the Management of Ascites in Cirrhosis : Chinese Society of Hepatology, Chinese Medical Association

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2024 Jul 9

PMID 38980598

Authors

Xiaoyuan Xu

Huiguo Ding

Jidong Jia

Lai Wei

Zhongping Duan

Chengwei Tang

Enqiang Linghu

Yuemin Nan

Ying Han

Jinghang Xu

Hui Zhuang

Affiliations

Soon will be listed here.

Abstract

In 2023, Chinese Society of Hepatology of Chinese Medical Association convened a panel of experts to update the Chinese guidelines on the management of ascites and associated complications in cirrhosis which was launched in 2017 and renamed this guidelines as "Guidelines on the Management of Ascites in Cirrhosis." This comprehensive resource offers essential recommendations for the diagnosis and treatment of cirrhotic ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome.

References

Reiberger T, Puspok A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C . Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr. 2017; 129(Suppl 3):135-158. PMC: 5674135. DOI: 10.1007/s00508-017-1262-3. View

Aithal G, Palaniyappan N, China L, Harmala S, Macken L, Ryan J . Guidelines on the management of ascites in cirrhosis. Gut. 2020; 70(1):9-29. PMC: 7788190. DOI: 10.1136/gutjnl-2020-321790. View

Zhang F, Feng Z, Zhang Y, Liu Z, Sun X, Jin S . Determination of the optimal volume of ascitic fluid for the precise diagnosis of malignant ascites. Saudi J Gastroenterol. 2019; 25(5):327-332. PMC: 6784429. DOI: 10.4103/sjg.SJG_547_18. View

Tsubokura M, Adegawa Y, Kojima M, Tanosaki R, Ohtake R, Kase Y . Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience. BMC Cancer. 2022; 22(1):268. PMC: 8919605. DOI: 10.1186/s12885-022-09298-6. View

Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K . Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021; 51(7):725-749. DOI: 10.1111/hepr.13678. View

Beyoglu D, Simillion C, Storni F, De Gottardi A, Idle J . A Metabolomic Analysis of Cirrhotic Ascites. Molecules. 2022; 27(12). PMC: 9228447. DOI: 10.3390/molecules27123935. View

Patel Y, Muir A . Evaluation of New-Onset Ascites. JAMA. 2016; 316(3):340-1. PMC: 5144153. DOI: 10.1001/jama.2016.7600. View

Biggins S, Angeli P, Garcia-Tsao G, Gines P, Ling S, Nadim M . Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021; 74(2):1014-1048. DOI: 10.1002/hep.31884. View

Bhardwaj R, Vaziri H, Gautam A, Ballesteros E, Karimeddini D, Wu G . Chylous Ascites: A Review of Pathogenesis, Diagnosis and Treatment. J Clin Transl Hepatol. 2018; 6(1):105-113. PMC: 5863006. DOI: 10.14218/JCTH.2017.00035. View

10.

Oblizajek N, Kamath P . Resolution of Loculated Chylous Ascites Using Intraperitoneal Fibrinolytic Therapy. Hepatology. 2021; 74(4):2293-2295. DOI: 10.1002/hep.31816. View

11.

Matchett C, Rattan P, McConnell J, Donato L, Simonetto D, Kamath P . Chylous Ascites: Reassessment of Diagnostic Criteria in Patients With Portal Hypertension. Am J Gastroenterol. 2022; 118(2):364-366. DOI: 10.14309/ajg.0000000000002072. View

12.

Nayi V, Wang Y, Galen B . When Appearance Is Everything: Chylous Ascites. Am J Med. 2018; 131(11):1314-1316. DOI: 10.1016/j.amjmed.2018.06.011. View

13.

Badillo R, Rockey D . Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore). 2014; 93(3):135-142. PMC: 4632908. DOI: 10.1097/MD.0000000000000025. View

14.

Garbuzenko D, Arefyev N . Hepatic hydrothorax: An update and review of the literature. World J Hepatol. 2017; 9(31):1197-1204. PMC: 5680207. DOI: 10.4254/wjh.v9.i31.1197. View

15.

Bernardi M . Optimum use of diuretics in managing ascites in patients with cirrhosis. Gut. 2009; 59(1):10-1. DOI: 10.1136/gut.2009.189506. View

16.

Angeli P, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E . Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut. 2009; 59(1):98-104. DOI: 10.1136/gut.2008.176495. View

17.

Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I . Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016; 51(7):629-50. DOI: 10.1007/s00535-016-1216-y. View

18.

Tang J, Wang Y, Han T, Mao Q, Cheng J, Ding H . Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterol. 2020; 20(1):391. PMC: 7678173. DOI: 10.1186/s12876-020-01536-0. View

19.

Bellos I, Kontzoglou K, Psyrri A, Pergialiotis V . Tolvaptan Response Improves Overall Survival in Patients with Refractory Ascites: A Meta-Analysis. Dig Dis. 2019; 38(4):320-328. DOI: 10.1159/000503559. View

20.

Uojima H, Kinbara T, Hidaka H, Sung J, Ichida M, Tokoro S . Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatol Res. 2016; 47(3):E14-E21. DOI: 10.1111/hepr.12716. View